EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immunohistochemistry-based investigation of MYC, BCL2, and Ki-67 protein expression and their clinical impact in diffuse large B-cell lymphoma in upper Northern Thailand

Phuttirak Yimpak iD, Kanokkan Bumroongkit, Adisak Tantiworawit iD, Thanawat Rattanathammethee iD, Sirinda Aungsuchawan, Teerada Daroontum iD

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0307253 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Phuttirak Yimpak und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomy, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Proto-Oncogene Proteins c-bcl-2, Ki-67 Antigen, Proto-Oncogene Proteins c-myc. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Faculty of Medicine, Chiang Mai University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diffuse large B-cell lymphoma (DLBCL) is an aggressive type of non-Hodgkin lymphoma (NHL) that accounts for approximately 25–40% of all NHL cases. The objective of this study was to investigate the protein expression, clinical impact, and prognostic role of MYC, BCL2, and Ki-67 in Thai DLBCL patients. A retrospective analysis was conducted on 100 DLBCL patients diagnosed between January 2018 and December 2019. Immunohistochemistry was used to assess the expression of MYC, BCL2, and Ki-67. The study revealed a significant association between extranodal involvement and positive cases of MYC and BCL2. MYC expressions were associated with Ki-67 expression, while BCL2 positivity was associated with the non-germinal center B-cell (non-GCB) subtype. However, there were no significant differences in the three-year overall survival (OS) and three-year progression-free survival (PFS) rates when using cut-off points of ≥ 40% for MYC, ≥ 50% for BCL2, and ≥ 70% for Ki-67. Notably, DLBCL cases with co-expression of MYC and BCL2 exhibited significantly inferior three-year OS compared to other cases (0% vs. 53%; p = 0.020). Multivariate analysis identified age ≥ 60 years and Eastern Cooperative Oncology Group (ECOG) performance status as independent prognostic factors. In conclusion, MYC, BCL2, and Ki-67 expression can serve as prognostic biomarkers; however, their prognostic value may vary based on the specific cut-off values used. Therefore, determining the appropriate threshold for each biomarker based on individual laboratory analyses and clinical outcomes is crucial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseProto-Oncogene Proteins c-bcl-2Ki-67 AntigenProto-Oncogene Proteins c-mycImmunohistochemistryHumansMaleFemaleMiddle AgedThailandAgedAdultRetrospective StudiesPrognosisAged, 80 and overBiomarkers, TumorYoung Adult

Substanzen

Proto-Oncogene Proteins c-bcl-2Ki-67 AntigenProto-Oncogene Proteins c-mycMYC protein, humanBCL2 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Anatomy, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
  • Department of Internal Medicine, Division of Hematology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
  • Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.

ORCID-Profile: Phuttirak Yimpak, Adisak Tantiworawit, Thanawat Rattanathammethee, Teerada Daroontum

Förderung

  • Faculty of Medicine, Chiang Mai University

Zitieren

APA

Yimpak, P., Bumroongkit, K., Tantiworawit, A., Rattanathammethee, T., Aungsuchawan, S., & Daroontum, T. (2024). Immunohistochemistry-based investigation of MYC, BCL2, and Ki-67 protein expression and their clinical impact in diffuse large B-cell lymphoma in upper Northern Thailand. PLOS ONE. https://doi.org/10.1371/journal.pone.0307253

Vancouver

Yimpak P, Bumroongkit K, Tantiworawit A, Rattanathammethee T, Aungsuchawan S, Daroontum T. Immunohistochemistry-based investigation of MYC, BCL2, and Ki-67 protein expression and their clinical impact in diffuse large B-cell lymphoma in upper Northern Thailand. PLOS ONE. 2024. doi:10.1371/journal.pone.0307253

BibTeX
@article{Yimpak2024,
  author = {Yimpak, Phuttirak and Bumroongkit, Kanokkan and Tantiworawit, Adisak and Rattanathammethee, Thanawat and Aungsuchawan, Sirinda and Daroontum, Teerada},
  title = {Immunohistochemistry-based investigation of MYC, BCL2, and Ki-67 protein expression and their clinical impact in diffuse large B-cell lymphoma in upper Northern Thailand},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0307253}
}
Kostenlos starten →